Vera Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $2.08B
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | During market hours | – | $-1.52 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 26, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | – | – | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 6, 2025 | Before market open | – | $-0.81 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 26, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 7, 2024 | Before market open | – | $-0.85 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 8, 2024 | Before market open | – | $-0.62 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 9, 2024 | Before market open | – | $-0.56 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 20, 2024 | Before market open | – | – | – |
Press releases
Announcements Vera Therapeutics filed with the SEC
Vera Therapeutics Announces TRUTAKNA (atacicept-vymj) Stabilized eGFR and Prevented Kidney
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Forward -looking statements Disclaime r This material has b een mad e
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Third Quarter
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Second Quarter
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vera Therapeutics, Inc. Corporate Presentation.
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vera Therapeutics Provides Business Update and Reports
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a
Results of operations · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
the Phase 2b ORIGIN Study of Atacicept in IgAN Presented at ASN Kidney Week 2024 October 28, 2024 © 2024 VERA THERAPEUTICS, INC.
Results of operations · Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases
Regulation FD disclosure · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Presents Positive 72-Week Data Showing eGFR
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
best-in-class therapy, the Company's expectations regarding completing the pivotal Phase 3 ORIGIN trial, the design and management of the Company's clinical trials, expectations regarding reporting results from such clinical trials and regulatory
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Forward Looking Statements Disclaimer This material has been made
Regulation FD disclosure · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Third Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Second Quarter Financial Results
Results of operations · EX-99.1 to Form 8-K
Forward Looking Statements Disclaimer This material has been made
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports First Quarter Financial Results
Results of operations · EX-99 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99 to Form 8-K
© 2023 VERA THERAPEUTICS, INC.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
© 2023 VERA THERAPEUTICS, INC.
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Provides Business Update and Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Vera Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K